Alison Fleming Net Worth

The estimated Net Worth of Alison B Fleming is at least $6.32 million dollars as of 3 December 2020. Alison Fleming owns over 5,967 units of Collegium Pharmaceutical Inc stock worth over $4,033,368 and over the last 8 years he sold COLL stock worth over $889,997. In addition, he makes $1,399,590 as Executive Vice President et Chief Technology Officer at Collegium Pharmaceutical Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Alison Fleming COLL stock SEC Form 4 insiders trading

Alison has made over 11 trades of the Collegium Pharmaceutical Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 5,967 units of COLL stock worth $114,805 on 3 December 2020.

The largest trade he's ever made was exercising 25,000 units of Collegium Pharmaceutical Inc stock on 8 November 2019 worth over $143,250. On average, Alison trades about 3,580 units every 34 days since 2017. As of 3 December 2020 he still owns at least 111,419 units of Collegium Pharmaceutical Inc stock.

You can see the complete history of Alison Fleming stock trades at the bottom of the page.

Alison Fleming biography

Dr. Alison B. Fleming Ph.D. serves as Executive Vice President, Chief Technology Officer of the Company. Dr. Fleming has served as our Executive Vice President and Chief Technology Officer since January 2017. Prior to being our Chief Technology Officer, Dr. Fleming led our development team as our Vice President, Product Development since October 2002. Prior to joining us, Dr. Fleming's academic research focused on implantable drug delivery systems for cancer therapy. Dr. Fleming is an inventor on several U.S. patents and pending patent applications, and has authored numerous scientific publications and poster presentations in the field of novel drug delivery systems and abuse-deterrent opioid formulations. Dr. Fleming graduated from the University of Massachusetts, Amherst in 1997 with a B.S. in Chemical Engineering and received a Ph.D. in Chemical and Biomolecular Engineering from Cornell University in 2002.

What is the salary of Alison Fleming?

As the Executive Vice President et Chief Technology Officer of Collegium Pharmaceutical Inc, the total compensation of Alison Fleming at Collegium Pharmaceutical Inc is $1,399,590. There are 5 executives at Collegium Pharmaceutical Inc getting paid more, with Joseph Ciaffoni having the highest compensation of $4,032,630.

How old is Alison Fleming?

Alison Fleming is 45, he's been the Executive Vice President et Chief Technology Officer of Collegium Pharmaceutical Inc since 2017. There are 17 older and 2 younger executives at Collegium Pharmaceutical Inc. The oldest executive at Collegium Pharmaceutical Inc is John Fallon, 72, who is the Independent Director.

What's Alison Fleming's mailing address?

Alison's mailing address filed with the SEC is C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072.

Insiders trading at Collegium Pharmaceutical Inc

Over the last 9 years, insiders at Collegium Pharmaceutical Inc have traded over $80,399,308 worth of Collegium Pharmaceutical Inc stock and bought 1,112,375 units worth $13,316,951 . The most active insiders traders include Group Holdings (Sbs) Adviso..., John Gordon Freund et David Hirsch. On average, Collegium Pharmaceutical Inc executives and independent directors trade stock every 35 days with the average trade being worth of $2,130,406. The most recent stock trade was executed by Shirley R. Kuhlmann on 5 September 2024, trading 20,225 units of COLL stock currently worth $773,809.

What does Collegium Pharmaceutical Inc do?

collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex

Complete history of Alison Fleming stock trades at Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc executives and stock owners

Collegium Pharmaceutical Inc executives and other stock owners filed with the SEC include:

• Joseph Ciaffoni,
  President, Chief Executive Officer, Director
• Scott Dreyer,
  Executive Vice President, Chief Commercial Officer
• Richard Malamut,
  Executive Vice President and Chief Medical Officer
• Paul Brannelly,
  Chief Financial Officer, Executive Vice President
• Shirley Kuhlmann,
  Executive Vice President, General Counsel, Secretary
• Alison Fleming,
  Executive Vice President, Chief Technology Officer
• Joseph J. Ciaffoni,
  Pres, CEO & Director
• Shirley R. Kuhlmann,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Richard Malamut,
  Exec. VP & Chief Medical Officer
• Michael Heffernan,
  Chairman of the Board
• Gino Santini,
  Lead Independent Director
• Garen Bohlin,
  Independent Director
• John Fallon,
  Independent Director
• Theodore Schroeder,
  Independent Director
• John Freund,
  Independent Director
• Gwen Melincoff,
  Independent Director
• Michael Thomas Heffernan B.S. Pharm, R.Ph.,
  Co-Founder & Chairman
• Michael Thomas Heffernan,
  Co-Founder & Chairman
• Rita Balice-Gordon,
  Director
• Scott Sudduth,
  Head of Technical Operations
• Marlo Manning,
  Head of HR
• Scott Dreyer,
  Exec. VP & Chief Commercial Officer
• Colleen Tupper,
  Exec. VP & CFO
• Jack Maroney,
  VP of Sales
• Bart J. Dunn,
  Exec. VP of Strategy & Corp. Devel.
• Alex Dasalla,
  Head of Investor Relations
• Barry S Duke,
  See remarks
• Eran Nadav,
  Director
• David Hirsch,
  Director
• Yasunori Kaneko,
  10% owner
• Venture Partners V Lp Skyli...,
  
• Capital Partners, Llc Tamme...,
  
• Thomas B Smith,
  EVP and Chief Medical Officer
• Colleen Tupper,
  EVP & Chief Financial Officer
• Patrick J Heron,
  Director
• Capital Partners, Llc Longi...,
  
• Healthcare Vi, L.P.Fhm Vi, ...,
  
• Group Holdings (Sbs) Adviso...,
  
• Venture Partners V Lp Skyli...,
  
• Neil F. Mc Farlane,
  Director